丁酸在非酒精性脂肪性肝病发生发展中的作用

党文呈; 邓烽丞; 李兆龙; 万燊燚; 张有成

doi:10.3969/j.issn.1001-5256.2020.04.046

丁酸在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2020.04.046

兰州大学第二医院普通外科

基金项目:

兰州大学第二医院“萃英科技创新”计划项目(CY2018-MS14)；甘肃省中医方药挖掘与创新转化重点实验室/甘肃省中药新产品创制省级工程实验室开放基金项目(ZYFYZH-KJ-2015-006)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 772
- HTML全文浏览量: 54
- PDF下载量: 198
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

The role of butyrate in the development and progression of nonalcoholic fatty liver disease

Department of General Surgery, Lanzhou University Second Hospital

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)特征为非酒精性因素所致的肝脂肪变性,其发病机制、疾病演变过程以及治疗和预防都逐渐受到广泛重视。目前关于肠道微生态与肥胖、糖尿病、心血管疾病等代谢性疾病关系的研究越来越多。近来也有许多研究发现肠道菌群代谢产物丁酸与NAFLD有着密切的关系,通过多种机制影响NAFLD的发生发展,如减轻炎症反应、抑制胰岛素抵抗以及减弱肝线粒体氧化应激等,研究丁酸与NAFLD疾病发病的关系有望为NAFLD的防治开辟新的途径。
- 非酒精性脂肪性肝病 /
- 丁酸 /
- 胃肠道微生物组
Abstract: Nonalcoholic fatty liver disease( NAFLD) is characterized by hepatic steatosis caused by nonalcoholic factors,and its pathogenesis,progression,treatment,and prevention have attracted more and more attention. At present,an increasing number of studies have been conducted on the association of intestinal microecology with various metabolic diseases such as obesity,diabetes,and cardiovascular diseases. Recent studies have found that butyrate,a metabolite of intestinal flora,is closely associated with NAFLD and can affect the development and progression of NAFLD through various mechanisms,such as alleviating inflammatory response,inhibiting insulin resistance,and reducing oxidative stress of liver mitochondria. Exploration of the association between butyrate and NAFLD is expected to provide a new approach for the prevention and treatment of NAFLD.
- non-alcoholic fatty liver disease /
- butyric acids /
- gastrointestinal microbiome

HTML全文

参考文献(38)

[1] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.

[2] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[3] CALZADILLA BERTOT L,ADAMS LA. The natural course of non-alcoholic fatty liver disease[J]. Int J Mol Sci,2016,17(5):774-786.

[4] WANG ZT,HU RH,XIONG Y. Progress of treatment on nonalcoholic fatty liver disease[J/CD]. Chin J Liver Dis(Electronic Edition),2018,10(4):48-53.(in Chinese)王中涛，胡荣华，熊勇．非酒精性脂肪性肝病治疗进展[J/CD]．中国肝脏病杂志(电子版)，2018,10(4):48-53.

[5] LIANG Y,LIN C,ZHANG Y,et al. Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate[J]. Inflammopharmacology,2018,26(4):1051-1055.

[6] ENDO H,NIIOKA M,KOBAYASHI N,et al. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats:New insight into the probiotics for the gut-liver axis[J]. PLo S One,2013,8(5):e63388.

[7] FAITH JJ,GURUGE JL,CHARBONNEAU M,et al. The long-term stability of the human gut microbiota[J]. Science,2013,341(6141):1237439.

[8] SALTZMAN ET,PALACIOS T,THOMSEN M,et al. Intestinal microbiome shifts,dysbiosis,inflammation,and non-alcoholic fatty liver disease[J]. Front Microbiol,2018,9:61.

[9] KOLODZIEJCZYK AA,ZHENG D,SHIBOLET O,et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med,2019,11(2):e9302.

[10] KAU AL,AHERN PP,GRIFFIN NW,et al. Human nutrition,the gut microbiome and the immune system[J]. Nature,2011,474(7351):327-336.

[11] CHEN Y,CAO YS,LIU XH. Short chain fatty acids and intestinal microflora[J]. Jiangxi Sci,2006,24(1):38-40,69.(in Chinese)陈燕，曹郁生，刘晓华．短链脂肪酸与肠道菌群[J]．江西科学，2006,24(1):38-40,69.

[12] WIEST R,ALBILLOS A,TRAUNER M,et al. Targeting the gutliver axis in liver disease[J]. J Hepatol,2017,67(5):1084-1103.

[13] FUKUDA S,TOH H,HASE K,et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate[J]. Nature,2011,469(7331):543-547.

[14] SAFARI Z,GRARD P. The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558.

[15] ZHANG WH,JIANG Y,ZHU QF,et al. Sodium butyrate maintains growth performance by regulating the immune response in broiler chickens[J]. Br Poult Sci,2011,52(3):292-301.

[16] PLGER S,STUMPFF F,PENNER GB,et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract[J]. Ann N Y Acad Sci,2012,1258:52-59.

[17] ZHOU D,PAN Q,XIN FZ,et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier[J]. World J Gastroenterol,2017,23(1):60-75.

[18] ZENG X,YANG J,HU O,et al. Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 signaling[J]. Antioxid Redox Signal,2019,30(2):163-183.

[19] CHEN M,HUI S,LANG H,et al. SIRT3 deficiency promotes high-fat diet-induced nonalcoholic fatty liver disease in correlation with impaired intestinal permeability through gut microbial dysbiosis[J]. Mol Nutr Food Res, 2019, 63(4):e1800612.

[20] FEINGOLD KR,MOSER A,SHIGENAGA JK,et al. Inflammation stimulates niacin receptor(GPR109A/HCA2)expression in adipose tissue and macrophages[J]. J Lipid Res,2014,55(12):2501-2508.

[21] KOH A,de VADDER F,KOVATCHEVA-DATCHARY P,et al.From dietary fiber to host physiology:Short-chain fatty acids as key bacterial metabolites[J]. Cell,2016,165(6):1332-1345.

[22] AGRAWAL S,DUSEJA AK. Non-alcoholic fatty liver disease:East versus west[J]. J Clin Exp Hepatol,2012,2(2):122-134.

[23] ROTTER V,NAGAEV I,SMITH U. Interleukin-6(IL-6)induces insulin resistance in 3T3-L1 adipocytes and is,like IL-8 and tumor necrosis factor-alpha,overexpressed in human fat cells from insulin-resistant subjects[J]. J Biol Chem,2003,278(46):45777-45784.

[24] BHAKTA HK,PAUDEL P,FUJII H,et al. Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B[J]. Arch Pharm Res,2017,40(11):1314-1327.

[25] LU V,BOGDANOVIC E,YU Z,et al. Combined Hyperglycemia-and hyperinsulinemia-induced insulin resistance in adipocytes is associated with dual signaling defects mediated by PKC-ζ[J]. Endocrinology,2018,159(4):1658-1677.

[26] ZHANG QN,XIAO Y,MIAO RX,et al. Changes in intestinal flora in nonalcoholic fatty liver disease:Their correlation with insulin resistance index,tumor necrosis factor-α，and interleukin-6[J]. J Clin Hepatol,2015,31(7):1078-1081.(in Chinese)张秋楠，肖英，苗瑞新，等．非酒精性脂肪性肝病患者肠道菌群变化与胰岛素抵抗指数、肿瘤坏死因子α和白细胞介素6的相关性分析[J]．临床肝胆病杂志，2015,31(7):1078-1081.

[27] RABOT S,MEMBREZ M,BRUNEAU A,et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism[J].FASEB J,2010,24(12):4948-4959.

[28] MATTACE RASO G,SIMEOLI R,RUSSO R,et al. Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet[J]. PLo S One,2013,8(7):e68626.

[29] HENAGAN TM,STEFANSKA B,FANG Z,et al. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation,obesity and insulin resistance through nucleosome positioning[J]. Br J Pharmacol,2015,172(11):2782-2798.

[30] CHRIETT S,ZERZAIHI O,VIDAL H,et al. The histone deacetylase inhibitor sodium butyrate improves insulin signalling in palmitate-induced insulin resistance in L6 rat muscle cells through epigenetically-mediated up-regulation of Irs1[J]. Mol Cel Endocrinol,2017,439:224-232.

[31] MOLLICA MP,MATTACE RASO G,CAVALIERE G,et al. Butyrate regulates liver mitochondrial function,efficiency,and dynamics in insulin-resistant obese mice[J]. Diabetes,2017,66(5):1405-1418.

[32] NAKAMURA S,TAKAMURA T,MATSUZAWA-NAGATA N,et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria[J]. J Biol Chem,2009,284(22):14809-14818.

[33] CAVALIERE G,TRINCHESE G,BERGAMO P,et al. Polyunsaturated fatty acids attenuate diet induced obesity and insulin resistance,modulating mitochondrial respiratory uncoupling in rat skeletal muscle[J]. PLo S One,2016,11(2):e0149033.

[34] GARCIA-TREVIJANO ER,IRABURU MJ,FONTANA L,et al.Transforming growth factor beta1 induces the expression of alpha1(I)procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells[J].Hepatology,1999,29(3):960-970.

[35] ISHII T,ITOH K,TAKAHASHI S,et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages[J]. J Biol Chem,2000,275(21):16023-16029.

[36] ZHANG HM,ZHANG Y. Melatonin:A well-documented antioxidant with conditional pro-oxidant actions[J]. J Pineal Res,2014,57(2):131-146.

[37] HATZIS G,ZIAKAS P,KAVANTZAS N,et al. Melatonin attenuates high fat diet-induced fatty liver disease in rats[J].World J Hepatol,2013,5(4):160-169.

[38] JIN CJ,ENGSTLER AJ,SELLMANN C,et al. Sodium butyrate protects mice from the development of the early signs of nonalcoholic fatty liver disease:Role of melatonin and lipid peroxidation[J]. Br J Nutr,2016:1-12.

施引文献

资源附件(0)

访问统计